Study of CHS-114 in Participants With Advanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorCoherus Oncology, Inc.
About this trial
This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
Eligibility criteria
Qualifiers
Arms 1a, 1b, 2, and 3
Participants must be ≥ 18 years of age.
For Arm 1a only, locally advanced or metastatic (Stage IV) solid tumor that has progressed during or after standard therapy and for whom no available therapies are appropriate (based on the judgment of the Investigator).
At least 1 measurable lesion per RECIST 1.1.
Disqualifiers
Arms 1a, 1b, 2, and 3
Previously received an anti-CCR8 antibody or anti-CCR8 targeted therapy.
History of Grade 4 allergic or anaphylactic reaction to any monoclonal antibody therapy or any excipient in the study drugs.
Major surgery within 4 weeks prior to Screening.
Trial design
Treatments tested in this trial
- CHS-114
- toripalimab
Treatment groups
87 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov